Abstract
Aim
The inability of drug molecules to cross the ‘Blood-Brain Barrier’ restrict the effective treatment of Alzheimer’s disease. Lipid nanocarriers have proven to be a novel paradigm in brain targeting of bioactive by facilitating suitable therapeutic concentrations to be attained in the brain.
Methods
The relevant information regarding the title of this review article was collected from the peer-reviewed published articles. Also, the physicochemical properties, and their in vitro and in vivo evaluations were presented in this review article.
Results
Administration of lipid-based nano-carriers have abilities to target the brain, improve the pharmacokinetic and pharmacodynamics properties of drugs, and mitigate the side effects of encapsulated therapeutic active agents.
Conclusion
Unlike oral and other routes, the Intranasal route promises high bioavailability, low first-pass effect, better pharmacokinetic properties, bypass of the systemic circulation, fewer incidences of unwanted side effects, and direct delivery of anti-AD drugs to the brain via circumventing ‘Blood-Brain Barrier’.
Acknowledgements
We acknowledge the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Government of India, for the financial support. The NIPER-R communication number for this publication is NIPER-R/Communication/190.
Disclosure statement
No potential conflict of interest was reported by the author(s).